-
May 01, 2024
GentiBio to Unveil Cutting-Edge Research at ASGCT Conference
-
March 23, 2024
GentiBio Announces Preclinical Data for GNTI-122, GentiBio’s Lead Candidate, an Autologous, Antigen-Specific Engineered T Regulatory Cell (EngTregs) for the Treatment of Newly Diagnosed and At-Risk Type 1 Diabetes (T1D)
-
November 15, 2022
GentiBio Named A BioSpace 2023 Best Places to Work
-
October 11, 2022
GentiBio Announces Preclinical Data Showing Antigen Specific Engineered Tregs Suppressing Pancreatic Inflammation and Potential Utility for Treatment and Prevention of Clinical Type 1 Diabetes (T1D)
-
September 15, 2022
GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases
-
August 10, 2022
GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases
-
June 24, 2022
GentiBio Announces Participation in Two Upcoming Investor Conferences
-
February 10, 2022
GentiBio Appoints Industry Veteran Chuck Silberstein as Chief Financial Officer
-
January 14, 2022
Rapport: To succeed, we must prepare ourselves for failure
-
January 06, 2022
Biospace: Top Life Sciences Startups to Watch in 2022
-
August 11, 2021
GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation
-
July 15, 2021
GentiBio and Forge Biologics Announce Viral Vector Contract Development and GMP Manufacturing Partnership
-
October 28, 2020
GentiBio Expands Leadership Team and Partnership with MIGAL to Help Advance Development of Engineered Regulatory T Cell Therapies
-
August 05, 2020
GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases
Toggle navigation